Video Series

An expert discusses how clinicians and institutions can streamline biomarker-driven therapy decisions by establishing rapid turnaround times for biopsies and pathology results, maintaining in-house testing capabilities, coordinating efficiently between interventional radiology and pathology teams, and ensuring insurance approvals don’t delay treatment initiation for patients who may deteriorate quickly.

Panelists discuss how the rapid adoption of subcutaneous (SubQ) oncology therapies creates challenges around clinical autonomy, infusion center sustainability, patient experience, and reimbursement models, highlighting the need for collaborative education and flexible care strategies to ensure patient-centered, financially viable implementation.

Panelists discuss how switching from intravenous (IV) to subcutaneous (SubQ) therapies requires proactive management of reimbursement, authorizations, and clinical workflows—emphasizing early payer coordination, billing oversight, and nurse retraining to ensure both financial sustainability and safe, efficient patient care.

Panelists discuss how NCCN guidelines are expected to incorporate quadruplet-based regimens as reasonable treatment approaches for transplant-ineligible patients, while emphasizing the need for personalized treatment strategies that consider individual patient frailty and high-risk genetics rather than applying uniform approaches across all older patients.

Panelists discuss how the CEPHEUS trial demonstrated that quadruplet therapy (daratumumab, bortezomib, lenalidomide, and dexamethasone) significantly improved minimal residual disease negativity rates compared to triplet therapy in transplant-ineligible multiple myeloma patients, achieving approximately 60% vs 47% 10–5 responses while maintaining manageable safety profiles.

A panelist highlights promising early-phase trial data on trispecific antibodies targeting multiple myeloma antigens and CD3, emphasizing their high response rates, manageable safety profiles, and potential to enhance treatment for heavily relapsed or high-risk patients while noting ongoing questions about optimal patient selection and their role alongside existing bispecific therapies.

A panelist discusses how oral combination therapy with decitabine-cedazuridine plus venetoclax shows activity in the relapsed/refractory acute myeloid leukemia setting, achieving responses even in patients with TP53 mutations, prior venetoclax exposure, or prior transplant, though the presenter questions whether 10 days of decitabine offers advantages over the standard 5-day regimen and emphasizes that these oral therapies can effectively extend beyond frontline treatment into salvage settings.

A panelist discusses how the shift from intravenous to oral AML therapies addresses significant quality-of-life concerns by eliminating the burden of spending 7 days per month in clinics for infusions (which can consume nearly half of a patient's remaining 15-month median survival time), while also improving clinic efficiency, though implementation requires careful attention to patient adherence, insurance coverage disparities that may penalize oral medications with higher co-pays, and monitoring for drug interactions.

Panelists discuss how payers seek good return on investment when evaluating expensive gene therapies, creating potential friction when innovative treatments come at significant costs, requiring ongoing dialogue between manufacturers, patients, payers, and physicians to determine appropriate value and access.

Panelists highlight that despite established guidelines, delays and gaps in molecular profiling—especially for KMT2A rearrangements—persist due to report complexity, misinterpretation, and misconceptions about patient eligibility, underscoring the urgent need for improved provider education, expert collaboration, and comprehensive testing to ensure accurate diagnosis, optimal treatment selection, and better patient outcomes in acute myeloid leukemia (AML).

Panelists discuss how data systems and registries should focus on improving care quality rather than just reimbursement, with patient empowerment strategies that encourage individuals to advocate for better treatments like de-prescribing harmful medications.

Panelists discuss how biomarkers, including genetic testing and tumor profiling, can help identify patients with RAS/MEK/ERK pathway activation or specific NF1 mutations, enabling more personalized and effective treatment with therapies like mirdametinib or gene therapies for progressive, symptomatic NF1-associated plexiform neurofibromas.

A panelist discusses how recent insights into dry eye disease highlight the importance of targeting both inflammation and tear production—showcasing treatments like cyclosporine drops and varenicline nasal spray—while emphasizing ongoing research aimed at addressing meibomian gland dysfunction and improving tear film stability for more effective, comprehensive care.

Panelists discuss how emerging biomarkers like neurofilament light protein, glial fibrillary acidic protein (GFAP), cervical cord atrophy, and phase rim lesions could enable earlier identification of patients at risk for progression, supporting more effective treatment decisions and payer coverage determinations based on longitudinal disability data rather than just relapse activity.

Panelists discuss how organizations must create system-wide cultural changes through staff training, appropriate clinical environments, evidence-based treatment access, and incentive structures that support rather than punish providers for addressing obesity as a chronic disease.

Panelists stress that timely and accurate diagnosis of KMT2A-rearranged acute myeloid leukemia (AML) is essential for personalized treatment planning, highlighting the need to overcome systemic delays in molecular testing, foster academic-community collaboration, and educate both clinicians and patients on the safety and importance of waiting for complete genetic data before initiating therapy.

Panelists discuss how the future of PAH treatment looks promising with potential for disease remission through reverse remodeling agents, emphasizing the need for continued research focus on patients with other forms of pulmonary hypertension and those with significant comorbidities.

Panelists discuss how cost-effectiveness analyses of newer therapies like sotatercept show substantial benefits in reducing clinical worsening events and potentially decreasing downstream costs through reduced hospitalizations and transplantations, supporting value-based payment models.

Panelists discuss how transitioning patients from intravenous (IV) to subcutaneous (SubQ) therapies demands a coordinated, multidisciplinary approach—integrating clinical judgment, electronic medical record (EMR) readiness, workflow adaptation, and patient-centered communication to ensure safe, efficient, and individualized care.

Panelists discuss that improving outcomes for patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) requires multifaceted efforts including developing patient-centered clinical measures, managing comorbidities, leveraging digital health tools for real-time monitoring, and addressing health equity to ensure timely, personalized care that truly reflects patients’ lived experiences.

Panelists discuss the shift toward patient-centered outcomes in idiopathic pulmonary fibrosis and progressive pulmonary fibrosis treatment, emphasizing quality of life and symptom relief alongside lung function, while expressing optimism that emerging therapies may eventually reverse or prevent fibrosis, fundamentally transforming disease management.

Panelists discuss how the rise of patient awareness around subcutaneous (SubQ) therapies calls for empathetic, evidence-based education, shared decision-making, and seamless system integration to ensure that treatment choices align with clinical appropriateness, patient preferences, and operational readiness.

An expert discusses how multidisciplinary collaboration can be enhanced through shared knowledge of available drugs and biomarkers among oncologists and pathologists, standardized interpretation methods across different cancer types, and clear communication about trial-specific algorithms to optimize treatment plans and ensure proper biomarker assessment.

Panelists discuss how emerging therapies like CAR T cells and bispecific antibodies may transform frontline treatment by potentially replacing transplant or changing induction regimens, while considering the cost implications and need for sustainable care models.

An expert discusses how the biggest barriers to incorporating antibody-drug conjugates (ADCs) include lacking biomarker knowledge and how payer restrictions can be overcome through early biomarker testing, proper documentation of target expression levels, and following FDA or National Comprehensive Cancer Network (NCCN) guidelines to ensure patient access to appropriate therapies.

Panelists discuss how early relapse in standard-risk patients represents a failure of current risk assessment methods and may require advanced sequencing technologies to identify hidden high-risk features that traditional fluorescence in situ hybridization testing misses.

A panelist discusses early clinical trial data on combining the B-cell maturation antigen–targeting bispecific antibody linvoseltamab with proteasome inhibitors carfilzomib and bortezomib in relapsed/refractory multiple myeloma, highlighting promising response rates, manageable toxicity profiles, and the potential for these combinations to enhance treatment efficacy pending longer-term follow-up.

Panelists discuss how patient perspectives on new therapies center around clinically meaningful outcomes and survival while balancing individual risk tolerance, with some patients willing to accept higher risks for potentially transformative treatments in devastating diseases.

Panelists discuss how exciting ongoing research efforts are expanding similar gene therapy technologies to other muscular dystrophies like FSHD and myotonic dystrophy, using strategies to knock down rather than restore gene expression for these autosomal dominant conditions.

A panelist discusses how the ASCERTAIN-V study demonstrated that an all-oral combination of decitabine-cedazuridine plus venetoclax achieved a 47% complete response rate and 15.5-month median overall survival in older, unfit AML patients, representing a potential new standard of care that eliminates the need for intravenous infusions and significantly reduces clinic time burden while serving as a backbone for future oral combination therapies.